BOONTON, N.J., Sept. 30, 2013 /PRNewswire/ -- Enteris BioPharma, Inc., an industry leader in innovative oral dosage formulations, and KeyBioScience, a wholly-owned subsidiary of Nordic Bioscience, today announced a strategic licensing agreement for Enteris' oral drug delivery and recombinant manufacturing technologies to advance the development of KeyBioScience's recently acquired family of proprietary metabolic peptides for various indications, including the treatment of Type 2 diabetes, obesity and other inflammatory conditions with high unmet medical and socioeconomic needs.
The licensing agreement with KeyBioScience marks the first significant revenue-generating partnership for Enteris since its inception in April 2013, and is representative of the company's broader "Feasibility-to-Licensing" strategy involving Peptelligence, its peptide and small molecule oral drug delivery platform. For KeyBioScience, the licensing agreement signals its transition to a clinical stage company following its formation by Nordic Bioscience.
Under the terms of the agreement, Enteris will license to KeyBioScience its oral drug delivery and recombinant manufacturing technologies, as well as become the exclusive provider of pre-clinical and clinical trial API and solid dosage form finished product and will receive both fee-for-service revenues and royalties based on net sales of the developed products.
Brian Zietsman, President and CFO of Enteris BioPharma, commented, "I cannot overemphasize the significance of this licensing agreement for Enteris and the excitement we share with Nordic Bioscience and its wholly-owned subsidiary KeyBioScience, especially given the tremendous potential therapeutic benefit and multi-billion dollar commercial potential of the compounds under development. Importantly, for Enteris, this licensing agreement showcases our unique ability to partner with global pharmaceutical companies to develop and progress orally delivered peptide and small molecule drugs utilizing our Peptelligence platform. Looking ahead, we are focused on expanding our portfolio of 'feasibility-to-licensing' agreements with both established and emerging biopharmaceutical companies that recognize the market opportunity afforded by formulating peptides and small molecules for oral drug delivery."
Dr. Morten Asser Karsdal, Professor and CEO of KeyBioScience, remarked, "Advancing the licensed peptides to the clinic is the first step in what we believe will ultimately become a new paradigm for peptide-based therapeutics and the treatment of metabolic disease. Our ability to both apply and leverage Enteris' Peptelligence platform will be critical to our success as we progress into advanced-stage clinical trials and potential commercialization."
Peptelligence is a clinically proven formulation technology that enables the oral delivery of BCS class II, III and IV peptide and small molecule compounds in a proprietary enteric-coated tablet formulation. Peptelligence has demonstrated a unique track record of clinical success across a range of compounds and therapeutic indications, including a positive outcome pivotal Phase 3 trial.
About Nordic Bioscience
Nordic Bioscience discovers and develops innovative medical treatments to help millions of people around the world suffering from serious, chronic, degenerative diseases such as osteoporosis and osteoarthritis, as well as metabolic disorders such as Type 2 diabetes. Since its incorporation in 1989, Nordic Bioscience has strived to revolutionize the in vitro diagnostics field, allowing the company to discover and design innovative drug development programs, in part through highly focused drug repositioning by serological measurements. The in-house developed biomarker platform, a unique measure of protein fingerprints, positions Nordic Bioscience as the leading scientific company within biomarker development.
About Enteris BioPharma
Enteris BioPharma, Inc. is a privately held, New Jersey-based biotechnology company offering innovative formulation solutions built around its proprietary drug delivery technologies.
Peptelligence has demonstrated a track record of clinical success across a range of compounds and therapeutic indications and has also been the subject of numerous feasibility studies and active development programs, several of which are in advanced stages of clinical development. For more information on Enteris BioPharma and Peptelligence, please visit http://www.EnterisBioPharma.com.
SOURCE Enteris BioPharma, Inc.